What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?

Journal of Family Practice

Volumn 50, Issue 11, 2001, Pages 927-928

  Weismantel, D ^a   Danis, P ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIFUNGAL AGENT; CREATINE KINASE; CYCLOSPORIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MACROLIDE; NICOTINIC ACID;

CLINICAL TRIAL; DOSE RESPONSE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TEST; MYALGIA; MYOPATHY; NOTE;

ANTICHOLESTEREMIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EVIDENCE-BASED MEDICINE; GEMFIBROZIL; HUMANS; LIVER FUNCTION TESTS; MUSCULAR DISEASES; PATIENT SELECTION; PRACTICE GUIDELINES; TIME FACTORS; TRANSAMINASES;

EID: 0035160045     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults